PURPOSE: We report a case of intravitreal bevacizumab injection for the treatment of choroidal neovascularization in morning glory syndrome. CASE SUMMARY: A 51-year-old male visited our hospital for a 1.5-year visual disturbance in his right eye. The patient's best-corrected visual acuity was 0.1 in the right eye. After fundus examination, we found characteristic findings of morning glory syndrome with submacular hemorrhage and serous retinal detachment in the right eye. Optical coherence tomography, fluorescein angiography and indocyanine green angiography were performed for evaluation. Retinoschisis, subretinal fluid, and choroidal neovascularization were detected, and thus bevacizumab was injected in the right eye. After intravitreal bevacizumab injection, retinoschisis was improved, and subretinal fluid was decreased. However, retinal pigment epithelial detachment was newly detected, and serous retinal detachment persisted. After 2 months, a second bevacizumab injection was performed. After these intravitreal bevacizumab injections at 1 and 2 months, visual acuity was 0.4 and 0.6, respectively. Visual acuity improved to 1.0 after 3 months. Visual acuity was maintained for at least 6 months with no relapse of choroidal neovascularization. CONCLUSIONS: The choroidal neovascularization in morning glory syndrome was effectively treated with intravitreal bevacizumab injections.
Angiography ; Choroidal Neovascularization* ; Fluorescein Angiography ; Hemorrhage ; Humans ; Indocyanine Green ; Male ; Middle Aged ; Recurrence ; Retinal Detachment ; Retinoschisis ; Subretinal Fluid ; Tomography, Optical Coherence ; Visual Acuity ; Bevacizumab

PURPOSE: To report a patient diagnosed with adult-onset vitelliform dystrophy (AOVD) who received an intravitreal injection of bevacizumab in both eyes. CASE SUMMARY: A 47-year-old female presented with blurred vision and metamorphopsia in both eyes. On color fundus photograph, small, round, yellowish dots on the foveola and subreitnal fluid were observed. Optical coherence tomography (OCT) showed thick hyperreflective structures in the retinal pigment epithelium (RPE) layer with serous retinal detachment and subretinal fluid. Despite an intravitreal injection of bevacizumab on both eyes, anatomical improvement was not observed on fundus photography and OCT.
Female ; Humans ; Intravitreal Injections* ; Middle Aged ; Photography ; Retinal Detachment ; Retinal Pigment Epithelium ; Subretinal Fluid ; Tomography, Optical Coherence ; Vision Disorders ; Vitelliform Macular Dystrophy* ; Bevacizumab

PURPOSE: To investigate the clinical availability of AL-Scan(R) (Nidek, GAMAGORI, Japan) by comparing anterior segment parameters measured with AL-Scan(R) and Pentacam(R) (Oculus, Wetzlar, Germany). METHODS: Seventy-three patients (117 eyes) who received refractive surgery at our hospital were tested with AL-Scan(R) and Pentacam(R). We compared measurements including anterior chamber depth, central corneal thickness, white-to-white, and corneal curvature. RESULTS: When comparing measurements obtained with AL-Scan(R) and Pentacam(R), the anterior chamber depth (p < 0.001), central corneal thickness (p < 0.001) and 2.4 mm zone K value (p = 0.038) showed significant differences; the white-to-white (p = 0.348) and 3.3 mm zone K value (p = 0.429) showed no significant differences. All AL-Scan(R) and Pentacam(R) parameters had a strong positive linear correlation (p < 0.001). The Bland-Altman plots showed a high degree of agreement between AL-Scan(R) and Pentacam(R) in all parameters except for anterior chamber depth. CONCLUSIONS: AL-Scan(R) is convenient to use clinically because simultaneous measurements of ocular biometry including axial length, intraocular lens power, and topography are possible. However, because differences in some anterior segment parameters exist when compared with Pentacam(R), measurements with AL-Scan(R) may require comparisons with other instruments.
Anterior Chamber ; Biometry ; Humans ; Lenses, Intraocular ; Refractive Surgical Procedures

PURPOSE: To investigate clinical availability of AL-Scan(TM) (Nidek, Gamagori, Japan) by comparing corneal refractive power with AL-Scan(TM), Autokeratometer(TM) (Topcon KR-1, Tokyo, Japan) and Pentacam(TM) (Oculus, Wetzlar, Germany) devices. METHODS: Seventy-one patients (142 eyes) who visited our hospital for refractive surgery were tested using AL-Scan(R), Autokeratometer and Pentacam(R) and corneal refractive power was compared among devices. RESULTS: When comparing measurements with AL-Scan(R), Autokeratometer and Pentacam(R), the mean corneal refractive power was 43.37 +/- 1.32 D (2.4 mm zone), 43.35 +/- 1.32 D (3.3 mm zone), 43.36 +/- 1.35 D, and 43.35 +/- 1.36 D respectively and showed no significant differences. Corneal refractive power had strongly positive linear correlation (p < 0.001) and Bland-Altman plots showed high degree of agreement among AL-Scan(R), Autokeratometer and Pentacam(R) devices. CONCLUSIONS: Because measuring ocular biometry with AL-Scan(R) including axial length, intraocular lens power calculation and topography simultaneously is possible, clinical use is convenient. Corneal refractive power was not different when compared with autokeratometer and Pentacam(R) devices, thus, AL-Scan(R) can be used in the clinical environment.
Biometry ; Humans ; Lenses, Intraocular ; Refractive Surgical Procedures

PURPOSE: To compare the refractive results of cataract surgery measured by applanation ultrasound and the new partial coherence interferometer, AL-scan. METHODS: Medical records of 76 patients and 104 eyes who underwent cataract surgery from January 2013 to June 2013 were retrospectively reviewed. Biometries were measured using ultrasound and AL-scan and intraocular lens power was calculated using the SRK-T formula. Automatic refraction examination was done 1 month after the operation, and differences between the ultrasound group and AL-scan group were compared and analyzed by mean absolute error. RESULTS: Mean axial length measured preoperatively by the ultrasound method was 23.53 +/- 1.17 mm while the lengths measured using the AL-scan were 0.03 mm longer than that of the ultrasound group (23.56 +/- 1.15 mm). However, there was not a significant difference in this finding (p = 0.638). Mean absolute error was 0.34 +/- 0.27 diopters in the ultrasound group and 0.36 +/- 0.31 diopters in AL-scan group, which showed no significant difference (p = 0.946) in precision of predicting postoperative refraction. CONCLUSIONS: Although the difference was not statistically significant, intraocular lens calculations done by the AL-scan were nearly similar in predicting postoperative refraction compared to those of applanation ultrasound, however more precise measurements may be obtained if the axial length is longer than 24.4 mm. Except in the case of opacity in the media, which makes obtaining measurements with the AL-scan difficult, AL-scan could be a useful biometry in cataract surgery.
Aged ; Anterior Chamber/pathology ; Axial Length, Eye/*pathology ; Biometry/methods ; Female ; Humans ; Interferometry/*instrumentation ; *Lens Implantation, Intraocular ; Lenses, Intraocular ; Light ; Male ; Middle Aged ; *Phacoemulsification ; Refraction, Ocular/physiology ; Reproducibility of Results ; Retrospective Studies ; Visual Acuity/physiology

PURPOSE: We report a case of dexamethasone intravitreal implant (Ozurdex(R); Allergan, Inc.) fragmentation during the injection procedure in macular edema due to central retinal vein occlusion. CASE SUMMARY: A 57-year-old man visited our hospital for visual disturbance in his right eye. The patient's best-corrected visual acuity was 0.02 in the right eye and 1.2 in the left eye. After fundus examination, the patient was diagnosed with central retinal vein occlusion with macular edema, thus bevacizumab was injected in the right eye. However, the macular edema did not improve, and a dexamethasone intravitreal implant was injected in the right eye. Immediately after the dexamethasone intravitreal implant injection, on fundus exam, the drug was observed to be fragmented into 3 pieces without any additional treatment. After 2 months, the patient's best-corrected visual acuity was 0.4 in the right eye and 1.2 in the left eye. Macular edema decreased according to optical coherence tomography. CONCLUSIONS: A case of dexamethasone intravitreal implant fragmentation during an injection procedure has not been previously reported in Korea. Although the drug fragmented, the treatment was effective without complications.
Antibodies, Monoclonal, Humanized ; Dexamethasone ; Eye ; Humans ; Korea ; Macular Edema ; Retinal Vein ; Visual Acuity ; Bevacizumab

PURPOSE: To report a case of Vogt-Koyanagi-Harada (VKH) disease in a pregnant patient treated with intravitreal triamcinolone injection. CASE SUMMARY: A 21-year-old female in the 19th week of gestation presented with bilateral blurring of vision associated with mild headache and tinnitus. Her initial best corrected visual acuity was 0.15 in the right eye and 0.3 in the left eye. Multiple serous retinal detachment and anterior chamber inflammation were observed, and VKH disease was diagnosed. Because of her pregnancy, the patient did not want high-dose systemic prednisolone therapy which may cause an abortion or low birth weight infant when used in a pregnant patient. Therefore, an intravitreal triamcinolone (4 mg/0.1 ml) injection was given in the right eye and topical steroid eye drops were used in the left eye. After 1 day, serous retinal detachment was significantly decreased and anterior chamber inflammation disappeared in the right eye. After 1 week, no serous retinal detachment was observed. In the left eye, serous retinal detachment was decreased after using steroid eye drops. After 10 days, serous retinal detachment disappeared but anterior chamber inflammation was still observed. After 1 month, best corrected visual acuity was 1.0 in both eyes and serous retinal detachment had not recurred. On follow-up, VKH disease had not recurred and a healthy normal weight infant was delivered. CONCLUSIONS: Intravitreal triamcinolone injection is an effective and safe treatment for VKH disease in pregnant women.
Anterior Chamber ; Eye ; Female ; Follow-Up Studies ; Headache ; Humans ; Infant ; Infant, Low Birth Weight ; Infant, Newborn ; Inflammation ; Ophthalmic Solutions ; Prednisolone ; Pregnancy ; Pregnant Women ; Retinal Detachment ; Tinnitus ; Triamcinolone* ; Uveomeningoencephalitic Syndrome* ; Vision, Ocular ; Visual Acuity ; Young Adult

PURPOSE: The purpose of this study was to determine the diurnal blood pressure variation with retinal vein occlusion (RVO) using 24-hour ambulatory blood pressure monitoring (24-hour ABPM). METHODS: The subjects in this study visited the department of ophthalmology from May 2012 to December 2012 and were diagnosed with RVO but had no history of hypertension (HTN). Non-dipper was defined as a nocturnal systolic blood pressure (SBP) decrease less than 10%. These values were used to compare the 24-hour ABPM values of the RVO and the control groups. RESULTS: The 24-hour ABPM values, with the exception of the mean nightly SBP, were statistically different whne the RVO group was compared with the control group. The odds of an RVO patient being a non-dipper compared to dipper were 1.81 times greater than in the control. Additionally, the clinical SBP and DBP in the RVO group were not significantly different when the HTN group and the non-HTN group were compared. In contrast, the mean 24-hour SBP and the mean DBP were significantly different in regard to HTN. CONCLUSIONS: Patients with RVO have a tendency to maintain high BP throughout the day and also during the night. A patient with non-dipper status can be at risk for RVO, even if the patient does not have HTN. Therefore, 24-hour ABPM is an effective management approach for HTN in addition to strict BP control in patients with RVO.
Blood Pressure ; Blood Pressure Monitoring, Ambulatory ; Humans ; Hypertension ; Ophthalmology ; Retinal Vein ; Retinal Vein Occlusion ; Retinaldehyde

PURPOSE: To evaluate the outcomes of Ahmed valve implantation in neovascular glaucoma patients who received intraoperative mitomycin C (MMC) and postoperative 5-fluorouracil (5-FU) after 24 months of follow-up. METHODS: A total of 40 eyes from 40 patients with neovascular glaucoma who received antiglaucomatous medication without previous glaucoma surgery were included in the present study. The patients were divided into 2 groups. The control group (20 eyes) underwent Ahmed valve implantation only and the study group (20 eyes) underwent Ahmed valve implantation and received intraoperative MMC and postoperative 5-FU. Failure was defined as the first occurrence of any of the following: 1) the first of 3 consecutive visits where intraocular pressure (IOP) was over 18 mmHg; 2) 20% IOP reduction from baseline; 3) the final number of topical medications was not reduced by at least two from baseline; 4) the need for additional surgery; or 5) the occurrence of a serious complication. RESULTS: In the control group, the cumulative success rate was 19.1% at 24 months. The cumulative success rate in the study group was 43.7% at 24 months. Serious complications such as endophthalmitis, valve exposure, or prolonged hypotony were not observed. CONCLUSIONS: The adjunctive use of intraoperative MMC and postoperative 5-FU with Ahmed valve implantation resulted in a high success rate and good IOP control and did not cause serious complications during the follow-up period.
Endophthalmitis ; Eye ; Fluorouracil ; Follow-Up Studies ; Glaucoma ; Glaucoma, Neovascular ; Humans ; Intraocular Pressure ; Mitomycin

BACKGROUND/AIMS: Gastroesophageal reflux disease (GERD) is common in asthma patients. Proton pump inhibitor (PPI) therapy improves symptoms of asthma in some patients. The objective of this study was to investigate endoscopic findings of GERD in asthma patients and to assess the effect of gastric acid suppression with the PPIs on symptom improvement and pulmonary function. METHODS: From 105 consecutive patients with GERD symptoms during follow up for asthma, 45 patients were enrolled. Patients enrolled to this study were asked about GERD symptoms before and after treating with PPI. Endoscopic findings were described according to Los Angeles classification. The improvement of asthma symptoms and follow-up pulmonary function test were investigated after administration of PPIs. RESULTS: Esophageal symptoms such as heartburn and acid reflux were present in 25 patients (55.6%), and patients without esophageal symptoms were 20 (44.4%). The degree of endoscopic abnormality was not significantly different between groups with or without esophageal symptoms. The improvement of symptoms was seen in 44 patients (97.8%) except 1 patient after administration of PPIs. The number of patients classified to the low-dose group was 7 patients (15.6%) and that of patients classified to the standard-dose group was 38 patients (84.4%). The follow-up pulmonary function test, peak expiratory flow rate (L/sec) was improved in 3 patients (3 of 7, 42.9%) of the low-dose group, and in 24 patients (24 of 38, 63.2%) of the standard-dose group. The improvement of ventilatory function was not significantly different according to dose of PPIs. CONCLUSIONS: Treatment with PPIs is expected to improve subjective symptoms and ventilatory function in asthma patients.
Adrenergic beta-Agonists/therapeutic use ; Adult ; Aged ; Asthma/*complications/drug therapy ; Female ; Follow-Up Studies ; Gastroesophageal Reflux/complications/*drug therapy ; Gastroscopy ; Glucocorticoids/therapeutic use ; Humans ; Male ; Middle Aged ; Peak Expiratory Flow Rate ; Proton Pump Inhibitors/*therapeutic use ; Treatment Outcome